StockTipsArenaBeta

BUY Lupin Limited — Prabhudas Lilladher

BUYLupin Limited

byPrabhudas LilladherHorizon: NA (inferred 1 year)7 Aug 2025via Institutional / Brokerage Research

Entry₹1,944.2Inferred
Target₹2,400
Total upside +23.44% (call closed)
Stop lossNot given
Exit₹2,4006 May 2026, 12:05 pm
Target hit+23.44%0.00%upside left
Follow Prabhudas Lilladher for new calls(67% target hit, 413 closed calls)Get alertsWatch LUPIN for new buy/sell callsGet alertsSee 13 active Long-term calls on LUPINSee 85 active Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 8 Sept, 9:39 pm IST
4 supporting0 opposing
Supports the BUY call (4)

Lupin Limited has received approval from the U.S. Food and Drug Administration (FDA) for its Glycerol Phenylbutyrate Oral Liquid.

BSE · Company Update·5 May · yesterday

(opens in new tab)

2 advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · adjacent horizon·4 May · yesterday

Lupin Limited has launched Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States.

BSE · Company Update·22 Apr · 2w ago

(opens in new tab)

3 other SEBI-registered advisors have active long-term BUY calls on this stock

Advisor consensus · same horizon·16 Feb · 3mo ago

Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.